Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

AHA 22 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the TRANSFORM-HF trial. This study aimed to compare the loop diuretics furosemide and torsemide in the treatment of patients with heart failure.

Over 2800 patients were enrolled in the trial and were randomized 1:1 to receive either treatment prior to hospital discharge. The oral dosing of furosemide and torsemide was given to patients in a 1mg:2mg ratio, and follow-ups were performed at 30-days, 6 months, and 12 months during the study. The strategy of torsemide had similar effectiveness compared with a strategy of furosemide in patients hospitalised with heart failure.

Recorded remotely from Hamilton and Durham, 2022.

Editor: Mirjam Boros
Broadcast Specialist: Dan Brent

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "AHA 22: Late-Breaker Discussion: The TRANSFORM-HF Trial" передвинте ползунок вправо